<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>AI-designed drug &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ai-designed-drug/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:27:28 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>AI-designed drug &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Insilico Medicine Publishes Phase IIa Results in Nature Medicine on Rentosertib, Novel AI-Designed TNIK Inhibitor for Idiopathic Pulmonary Fibrosis</title>
		<link>https://bioengineer.org/insilico-medicine-publishes-phase-iia-results-in-nature-medicine-on-rentosertib-novel-ai-designed-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 03 Jun 2025 17:05:45 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[AI-designed drug]]></category>
		<category><![CDATA[generative AI in drug discovery]]></category>
		<category><![CDATA[idiopathic pulmonary fibrosis treatment]]></category>
		<category><![CDATA[Phase IIa clinical trial]]></category>
		<category><![CDATA[TNIK inhibitor]]></category>
		<guid isPermaLink="false">https://bioengineer.org/insilico-medicine-publishes-phase-iia-results-in-nature-medicine-on-rentosertib-novel-ai-designed-tnik-inhibitor-for-idiopathic-pulmonary-fibrosis/</guid>

					<description><![CDATA[In a groundbreaking advancement in pharmaceutical science, Insilico Medicine has unveiled the first proof-of-concept clinical validation of a drug discovered entirely through generative artificial intelligence (AI). Published on June 3, 2025, in the prestigious journal Nature Medicine, this milestone study introduces Rentosertib (ISM001-055), a novel TNIK kinase inhibitor developed for idiopathic pulmonary fibrosis (IPF). This [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">248101</post-id>	</item>
	</channel>
</rss>
